Table 1 visual acuity and OCT signs at presentation and during the follow up
At Presentation | After three bevacizumab injections | Final | |
|---|---|---|---|
VA (LogMar) | 0.59 ± 0.5 | 0.49 ± 0.5 (p = 0.009) | 0.59 ± 0.6 (p = 0.698) |
CMT (μm) | 402.1 ± 130.8 | 322.0 ± 96.8 (p = 0.00) | 305.2 ± 108.5 (p = 0.00) |
Choroidal thickness (μm) | 228 ± 76.9 | 216.5 ± 66.0 (p = 0.041) | 223.1 ± 86.1 (p = 0.457) |
SRF | 86.4% | 47.70% (p = 0.022) | 25.50% (p = 0.312) |
IRF | 27.30% | 13.60% (p = 0.00) | 27.90% (p = 0.079) |
submacular Hemorrhage | 11.4% | 9.10% (p = 0.00) | 0% (p = 0.00) |
Pachyvessels | 77.30% | 77.30% | 77.30% |